Markets

Insider Trading

Hedge Funds

Retirement

Opinion

UBS: CBRE Group, Inc. (NYSE:CBRE) Is A Bottom-Ranked Quant Stock

We recently made a list of UBS’ Bottom Quant Stocks In AI, IT, Healthcare & Others: 29 Stocks In All Sectors. In this piece, we will look at where CBRE Group, Inc. (NYSE:CBRE) ranks on the list of UBS’ bottom quant stocks.

With November 2024 having settled in and the US presidential election in its final stages, investors are also digesting the results of the latest earnings season. As had been the case for the first and second-quarter earnings season, Q3 was also focused on artificial intelligence. While Wall Street’s AI GPU darling, the firm whose shares are up an unbelievable 206% over the past twelve months, is yet to report its earnings, other consequential firms have got the ball rolling.

Two of these are among the most important players in the software segment of the AI industry. The first is known for its tightly-knit relationship with the firm behind ChatGPT, OpenAI. The second is the world’s largest social media company that has made waves in the AI industry with its open-source Llama AI foundational AI model. Starting from the former, its ability to generate AI profits primarily through its cloud computing division is baked into the narrative.

Since its earnings report, the shares are down by 4.9%. This is even though the firm’s revenue and earnings per share of $65.59 billion and $3.30 beat analyst estimates of $64.51 billion and $3.10. Along with the earnings and revenue beat, the software company’s Azure cloud computing business which also includes its enterprise-focused AI services grew by 33% annually or 34% on a constant currency basis. These also beat analyst estimates, so on the surface, one would expect the shares to rise.

However, Wall Street isn’t always focused on current performance, and for AI stocks, their narratives are built on future expectations. These expectations are priced into the stocks. For the software company, its weak guidance is at the center of the poor share price performance as the current quarter revenue guidance of $68.1 billion to $69.1 billion missed Wall Street estimates of $69.83 billion by more than half a billion dollars.

The software company was joined by the social media firm to report its earnings on the same day. The Facebook parent’s shares are also down since the earnings report as they have lost 3.3% after recovering from the bottom of a 5.3% loss. Its earnings report, like the post-report stock performance, also mirrors the software company’s results to an extent. For starters, the social media firm also beat analyst revenue and EPS estimates. It posted $40.59 billion in revenue and $6.03 in earnings per share to beat analyst estimates of $40.29 billion and $5.25. Driving the beat was higher advertising revenue which grew by 18.7% annually to sit at $39.9 billion.

However, while the firm’s net income jumped by 35% to touch $15.7 billion, it was the slowest growth in over a year. Additionally, the firm reported that it had 3.29 billion active daily users during the third quarter, which was lower than the 3.31 billion in analyst estimates. Another factor that didn’t impress investors was its AI-driven capital expenditure. The firm raised the lower end of its full-year capital expenditure to $38 billion from $37 billion and kept the high end intact at $40 billion. Higher expenditures increase the return that investors expect and reduce payouts in the form of dividends and share buybacks. Consequently, the stock tumbled after the earnings report.

These two AI-driven earnings reports are part of a market that is now facing lower rates, higher growths, and the culmination of a bitterly fought presidential election. In a recent report, investment bank UBS took an optimistic view of the US stock market. It noted that from “a macro perspective, the combination of slowing but durable economic growth, healthy earnings growth, and continued Fed rate cuts is supportive.” The bank is also optimistic about AI and particularly about the broader category of firms apart from the GPU designer that has seen most of the share price gains so far.

In its report, it notes that “AI-related companies that span semiconductors, cloud service providers, devices, and data centers account for over one-third of the S&P 500 by market cap. We expect continued growth in AI investment spending to drive revenues and profits.”  However, according to UBS, AI is not the only lucrative stock market sector offered by the US stock market. The bank adds that the “S&P 500 also offers exposure to secular growth in longevity through various US medical device companies. Many US companies are also playing leading roles in the energy transition via electric vehicles, renewables, and energy efficiency.”

On the topic of interest rate cuts, the report outlines that “50bps cuts at similar labor market conditions as today have historically been positive for equities.” These labor conditions are determined by the 3-month average for US nonfarm payrolls, and UBS also believes that rate cuts by the Federal Reserve can reverberate across global markets. It notes that “Historically, Fed rate cuts of more than 50bps when the market was within 1% of all-time highs have been rare. It only happened during the Volcker era in the mid 1980s. The S&P 500 rallied more than 20% in the 12 months following the jumbo cuts. Also, Fed rate cuts tend to reverberate positively across global equity markets, with Asia ex-Japan and emerging markets as the primary beneficiaries outside the US.”

Finally, with the 2024 US Presidential Election over, the bank’s report released ahead of the election also commented on the outcomes on Wall Street. It shared that “S elections are a short-term risk; for instance, if former President Donald Trump is elected, markets may quickly price potential tariffs. However, we would see dips as buying opportunities and recommend gradually phasing in equity exposure.”

Our Methodology

To make our list of UBS stocks with improving quantitative indicators, we chose the firm’s top stocks that are seeing improvements in EPS growth, P/E ratio, and other indicators. Stocks within each sector were ranked by the number of hedge funds that had bought the shares during Q2 2024. The sectors themselves were ranked by the cumulative number of funds that had been invested in the firms in descending order.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).

A graph plotting the trends and performance of stocks on the public equity markets.

CBRE Group, Inc. (NYSE:CBRE)

Number of Hedge Fund Investors In Q2 2024: 54

Sector: Real Estate

CBRE Group, Inc. (NYSE:CBRE) is one of the largest real estate services firms in the US. It has a diversified product portfolio through which the firm provides leasing advice, mortgage loans, property management services, and mortgages. This gives CBRE Group, Inc. (NYSE:CBRE) a wide exposure to the broader real estate industry, which is a sector that doesn’t perform well when interest rates are high. Yet, with the high-rate era now at its end, CBRE Group, Inc. (NYSE:CBRE) is also seeing sizable catalysts in the stock market. To understand these catalysts, consider the share price performance between January and June and from July to November start. During the first period, the stock lost 7.8% while during the second period, it gained 53.6%. This strong latter-half performance has come on the back of rising leasing activity as corporate budgets lighten and a recovery in the global property market during the third quarter.

CBRE Group, Inc. (NYSE:CBRE)’s management commented on this recovery during the Q3 2024 earnings call. Here is what they said:

“Advisory net revenue exceeded expectations, supported by leasing strength in the beginning of a recovery in property sales revenue. We continue to benefit from our strong position in the office leasing market. In fact, global office leasing revenue reached a new high for any Q3, increasing by 26% better than we expected. Greater certainty about the economic outlook is supporting occupier decision-making across primary and secondary markets, particularly in the U.S. and Europe.

As expected, demand is skewed towards the highest quality space that will encourage employees to return to the office. Global property sales returned to growth with a 14% revenue increase, exceeding expectations. Revenue grew across all global regions. In the U.S., property sales revenue rose almost 20%, driven by stronger activity in multifamily and retail.”

Overall, CBRE ranks 23rd on our list of UBS’ bottom quant stocks in AI, IT, healthcare & other sectors. While we acknowledge the potential of CBRE as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CBRE but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…